Hui Hong

This inventor holds 24 USPTO granted patents, plus 5 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Rigel Pharmaceuticals, Incorporated, Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hui Hong. Retrieved from https://idiyas.com/inventor/hui-hong

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24

% Patents Active = 79.2

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 6.2

ph-index = 7

Forward Citations = 85(Granted Patents)

Location History:

Palo Alto, CA (US) (2010 - 2016)
Foster City, CA (US) (2015 - 2022)

Company Filing History:

23 out of 492

Rigel Pharmaceuticals, Incorporated

patents

2 out of 3,737

Bristol-Myers Squibb Compnay

patents

1 out of 41

Bristol Meyers Squibb Company

patents

4. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...

Areas of Expertise:

TGF-beta Inhibitors

JAK Kinase Inhibitors

Carboxamide Compounds

Pyrimidine-2-Amine

AMPK Activators

Sulfonamide Compounds

HCV Treatment

N-Substituted Compounds

Pharmaceutical Compositions

Heterocycles

Benzisothiazoles

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11352360 - TGF-beta inhibitors (2022-06-07),

2. 10287295 - TGF-β inhibitors (2019-05-14),

3. 9884868 - TGF-beta inhibitors (2018-02-06),

4. 9624229 - Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases (2017-04-18),

5. 9353111 - Carboxamide compounds and methods for using the same (2016-05-31),

6. 9255085 - Carboxamide compounds and methods for using the same (2016-02-09),

7. 9181220 - N-substituted-heterocycloalkyloxybenzamide compounds and methods of use (2015-11-10),

8. 9174964 - AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same (2015-11-03),

9. 9062052 - Carboxamide compounds and methods for using the same (2015-06-23),

10. 8895578 - Carboxamide, sulfonamide and amine compounds and methods for using the same (2014-11-25),

11. 8871770 - Carboxamide compounds and methods for using the same (2014-10-28),

12. 8846600 - Carboxamide compounds and methods for using the same (2014-09-30),

13. 8785449 - Carboxamide compounds and methods for using the same (2014-07-22),

14. 8735418 - Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases (2014-05-27),

15. 8697727 - N-substituted-heterocycloalkyloxybenzamide compounds and methods of use (2014-04-15),

Title: Innovations by Hui Hong in Pharmaceutical Patents

Introduction: Hui Hong, based in Palo Alto, California, is a notable inventor with a remarkable portfolio of 24 patents. His contributions to the field of pharmaceuticals are particularly significant, focusing on compounds that hold potential in treating various diseases by targeting TGF-beta signaling pathways.

Latest Patents: Among his latest innovations are TGF-beta inhibitors, which include imidazole and thiazole compounds. These patents disclose specific pharmaceutical compositions and methods for their use. One notable embodiment involves a compound with a defined structure and its pharmaceutically acceptable salts, prodrugs, and N-oxides, including solvates and hydrates. This invention aims to inhibit TGF-beta, showcasing the potential to treat diseases by effectively blocking TGF-beta signaling.

Career Highlights: Hui Hong has made impactful contributions while working at renowned companies such as Rigel Pharmaceuticals and Bristol-Myers Squibb Company. His experience in these firms has equipped him with extensive knowledge and expertise in pharmaceutical research and development, further enhancing his innovative capabilities.

Collaborations: Hui has collaborated with several talented individuals throughout his career, including Rajinder Paul Singh and Ihab S. Darwish. These partnerships have played a crucial role in fostering advancements in his research and innovations, particularly in the realm of therapeutics targeting critical biological pathways.

Conclusion: Hui Hong's innovations, reflected in his extensive patent portfolio, demonstrate his commitment to advancing pharmaceutical science. His work on TGF-beta inhibitors represents a significant step toward developing new treatment options for diseases, showcasing his importance in the field of medical research and patenting.

Profile summary based on public USPTO records.